当前位置:首页 - 行情中心 - 名臣健康(002919) - 财务分析 - 利润表

名臣健康

(002919)

  

流通市值:45.90亿  总市值:46.27亿
流通股本:2.64亿   总股本:2.67亿

利润表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、营业总收入1,078,874,052.86711,668,800.05361,419,226.731,380,254,020.51
  营业收入1,078,874,052.86711,668,800.05361,419,226.731,380,254,020.51
二、营业总成本1,031,137,681.82673,425,511.37340,518,894.231,279,892,804.36
  营业成本503,196,868.03329,242,376.05157,926,236.96655,621,816.29
  税金及附加3,271,680.572,042,234.89724,315.215,358,600.75
  销售费用417,668,460.24267,349,883.84146,167,531.44443,621,398.89
  管理费用66,119,377.7846,851,976.3822,038,110.4106,043,406.6
  研发费用40,483,039.4727,805,680.8513,676,400.0269,410,518.02
  财务费用398,255.73133,359.36-13,699.8-162,936.19
  其中:利息费用873,631.07466,641.42232,511.071,584,358.09
  其中:利息收入518,854.47343,491.46198,709.941,051,535.16
三、其他经营收益
  加:公允价值变动收益460,242.24309,669.4139,580.85376,726.21
  加:投资收益217,482.72147,972.1379,033.26147,045.64
  资产处置收益237,163.74233,240.96-182,061.134,381,300.68
  资产减值损失(新)-2,863,121.62-267,678.53--24,415,616.12
  信用减值损失(新)-8,617,104.41-1,809,177.9-6,417,941.31-49,924,933.59
  其他收益1,386,702.34341,247.68255,364.28406,211.75
四、营业利润38,557,736.0537,198,562.4214,774,308.4531,331,950.72
  加:营业外收入45,195.7237,718.355,009.82866,747.34
  减:营业外支出738,235.08578,529.151,560.844,719,881.01
五、利润总额37,864,696.6936,657,751.6214,777,757.4327,478,817.05
  减:所得税费用-4,538,555.32-4,399,777.762,030,124.67-19,238,335.84
六、净利润42,403,252.0141,057,529.3812,747,632.7646,717,152.89
(一)按经营持续性分类
  持续经营净利润42,403,252.0141,057,529.3812,747,632.7646,717,152.89
(二)按所有权归属分类
  归属于母公司股东的净利润42,549,813.9541,062,613.1212,713,011.4946,719,608.82
  少数股东损益-146,561.94-5,083.7434,621.27-2,455.93
  扣除非经常损益后的净利润41,217,097.2640,763,947.6212,608,385.945,983,843.85
七、每股收益
  (一)基本每股收益0.160.150.050.18
  (二)稀释每股收益0.160.150.050.18
九、综合收益总额42,403,252.0141,057,529.3812,747,632.7646,717,152.89
  归属于母公司股东的综合收益总额42,549,813.9541,062,613.1212,713,011.4946,719,608.82
  归属于少数股东的综合收益总额-146,561.94-5,083.7434,621.27-2,455.93
公告日期2025-10-292025-08-292025-04-292025-04-29
审计意见(境内)标准无保留意见
TOP↑